resisttb
- Jan 19
- 1 min read

Price reduction paves the way for expanded access to highly effective MDR-TB

Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%. Pretomanid is part of two new treatment regimens with high efficacy and shorter treatment durations recently recommended by the World Health Organization (WHO) as the preferred regimens for most drug-resistant tuberculosis patients. Read more here.

Recent Posts

See All

World TB Day 2023 Campaign Toolkit

The Stop TB Partnership today is releasing the campaign toolkit for this year’s World TB Day, 24 March 2023 Yes! We Can End TB. The theme brings attention toTB and our collective power to end TB by 20

Sutezolid with 3-drug combo appears safe and effective in multidrug-resistant TB

Adding the oxazolidinone antibiotic sutezolid to a three-drug combination appeared to be safe and effective for people with multidrug-resistant tuberculosis (TB), according to a dose-finding phase II

TAG's TB Treatment Pipeline Report Published

TAG has released its Pipeline Report regarding TB Treatment updates and results from trials completed in 2022 written by Lindsay McKenna. Read the report here!